Abstract
It has become increasingly clear that anti-tuberculosis regimens need optimization. Information gained using pharmacokinetics/ pharmacodynamics (PK/PD) methods in hollow fiber and animal model studies, in conjunction with Monte Carlo simulations, can be used to achieve this goal. PK/PD models of anti-tuberculosis drugs in hollow fibers, mice and guinea pigs have been remarkably concordant. Using exposures derived in these models it has been shown that the standard doses of pyrazinamide, rifampin, and ethambutol should be increased for a better efficacy, while doses of isoniazid need to be individualized. In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824.
Keywords: Mycobacterium tuberculosis, PK-PD, models, dosing schedule, dose optimization, bacteria, monotherapy, isoniazid, Fluoroquinolones, meningitis
Current Pharmaceutical Design
Title: In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Volume: 17 Issue: 27
Author(s): Shashikant Srivastava and Tawanda Gumbo
Affiliation:
Keywords: Mycobacterium tuberculosis, PK-PD, models, dosing schedule, dose optimization, bacteria, monotherapy, isoniazid, Fluoroquinolones, meningitis
Abstract: It has become increasingly clear that anti-tuberculosis regimens need optimization. Information gained using pharmacokinetics/ pharmacodynamics (PK/PD) methods in hollow fiber and animal model studies, in conjunction with Monte Carlo simulations, can be used to achieve this goal. PK/PD models of anti-tuberculosis drugs in hollow fibers, mice and guinea pigs have been remarkably concordant. Using exposures derived in these models it has been shown that the standard doses of pyrazinamide, rifampin, and ethambutol should be increased for a better efficacy, while doses of isoniazid need to be individualized. In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824.
Export Options
About this article
Cite this article as:
Srivastava Shashikant and Gumbo Tawanda, In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470192
DOI https://dx.doi.org/10.2174/138161211797470192 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and In Vitro Anti-microbial Evaluation of Ethylene/ Propylene-1H-1,2,3-Triazole-4-Methylene-tethered Isatin-coumarin Hybrids
Current Topics in Medicinal Chemistry Novel 2-hydrazino-pyrimidin-4(3H)-one Derivatives with Pseudofunctional- Similarity to Siderophores as Potential Antimycobacterial Agents
Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Snake Venom Proteins and Peptides as Novel Antibiotics Against Microbial Infections
Current Proteomics Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy
Recent Patents on Anti-Infective Drug Discovery Synthesis of spirobiindane based bis-flavanones and bis-chroman-4-ones by Kabbe Reaction
Letters in Organic Chemistry Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry Nanochemistry-Based Immunotherapy for HIV-1
Current Medicinal Chemistry Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology Structure and Function of MPN (Mpr1/Pad1 N-terminal) Domain- Containing Proteins
Current Protein & Peptide Science γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Preparation and Characterization of Solid Lipid Nanoparticles-A Review
Current Drug Discovery Technologies Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents
Current Clinical Pharmacology Microarray Analysis of Whole Genome Expression of Intracellular Mycobacterium tuberculosis
Current Molecular Medicine Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery Monocyte and Macrophage Dysfunction as a Cause of HIV-1 Induced Dysfunction of Innate Immunity
Current Molecular Medicine Targeting the Human Macrophage with Combinations of Drugs and Inhibitors of Ca2+ and K+ Transport to Enhance the Killing of Intracellular Multi-Drug Resistant Mycobacterium tuberculosis (MDR-TB) - a Novel, Patentable Approach to Limit the Emergence of XDR-TB
Recent Patents on Anti-Infective Drug Discovery Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology